College of Health, Medicine and Wellbeing, The University of Newcastle, Newcastle, NSW, Australia.
Hunter Medical Research Institute, Lot 1, Kookaburra Circuit, Newcastle, NSW, 2305, Australia.
Stem Cell Rev Rep. 2022 Dec;18(8):2606-2628. doi: 10.1007/s12015-022-10429-6. Epub 2022 Jul 28.
Mesenchymal stem cell (MSC) therapy has gained significant traction in the context of cardiovascular repair, and have been proposed to exert their regenerative effects via the secretion of paracrine factors. In this systematic review, we examined the literature and consolidated available evidence for the "paracrine hypothesis". Two Ovid SP databases were searched using a strategy encompassing paracrine mediated MSC therapy in the context of ischemic heart disease. This yielded 86 articles which met the selection criteria for inclusion in this study. We found that the MSCs utilized in these articles were primarily derived from bone marrow, cardiac tissue, and adipose tissue. We identified 234 individual protective factors across these studies, including VEGF, HGF, and FGF2; which are proposed to exert their effects in a paracrine manner. The data collated in this systematic review identifies secreted paracrine factors that could decrease apoptosis, and increase angiogenesis, cell proliferation, and cell viability. These included studies have also demonstrated that the administration of MSCs and indirectly, their secreted factors can reduce infarct size, and improve left ventricular ejection fraction, contractility, compliance, and vessel density. Furthering our understanding of the way these factors mediate repair could lead to the identification of therapeutic targets for cardiac regeneration.
间充质干细胞 (MSC) 治疗在心血管修复方面受到了广泛关注,并被提出通过旁分泌因子的分泌来发挥其再生作用。在本系统评价中,我们查阅了文献并综合了旁分泌 MSC 治疗在缺血性心脏病中的可用证据,来验证“旁分泌假说”。我们使用包含间充质干细胞治疗的策略,在 Ovid SP 数据库中进行了搜索,共得到 86 篇符合纳入本研究标准的文章。我们发现,这些文章中使用的间充质干细胞主要来源于骨髓、心脏组织和脂肪组织。我们在这些研究中鉴定了 234 种单独的保护因子,包括 VEGF、HGF 和 FGF2,这些因子被认为以旁分泌的方式发挥作用。本系统评价中汇集的数据确定了分泌的旁分泌因子,这些因子可以减少细胞凋亡,增加血管生成、细胞增殖和细胞活力。这些研究还表明,MSC 的给药及其间接的分泌因子可以减少梗死面积,改善左心室射血分数、收缩性、顺应性和血管密度。进一步了解这些因子介导修复的方式可能会为心脏再生的治疗靶点的确定提供线索。